Assay development Princ Tech/Scientist

Zealand Pharma A/S; Gladsaxe Kommune; On-site; DKK 700,000 - 1,100,000; Full time

Job summary

Zealand Pharma A/S is seeking a Laboratory-based Principal Technologist or Scientist to join the Department of Pharmacokinetics, Immunogenicity & Bioanalytical Sciences. You will develop and qualify high-quality assays to detect novel peptide therapeutics and characterize immunogenicity during preclinical and clinical development.

You will support assay transfers to CROs, generate critical reagents, and contribute to data analysis and documentation in a collaborative, English-speaking

Qualifications

• Laboratory technologist qualification (e.g., biomedical laboratory technology) or a scientific degree (e.g., biology, biochemistry, pharmacy) with a clear interest in hands‑on laboratory work
• 5 to 10 years of hands‑on experience in development and qualification of assays including immunogenicity assays, biomarker assays, and quantitative ligand binding assays (cell‑based and ligand binding formats)
• Good understanding of various analytical techniques used for biomolecules (e.g., ELISA, electrochemiluminescence, affinity chromatography, surface plasmon resonance, or related methods)
• Thorough understanding of analytical methods for quantifying, detecting, and characterizing drug‑induced immunogenicity
• Excellent documentation and data analysis skills
• Proven ability to master core processes independently while being an effective team collaborator
• Proficient in English, both written and oral communication

Responsibilities

• Development and qualification of cell-based and ligand binding immunogenicity assays (anti-drug antibodies and neutralizing antibodies)
• Support general ligand binding assay development, qualification, and sample analysis as required
• Production, purification, and characterization of critical reagents
• Cell culture maintenance and optimization for assay purposes
• Support assay transfer and validation to contract research organizations (CROs)
• Data analysis, interpretation, and comprehensive documentation

Skills

Immunogenicity assays

Biomarker assays

Ligand binding assays

Cell-based assays

ELISA

Electrochemiluminescence

Surface plasmon resonance

Data analysis

Education

Biomedical laboratory technology OR biology/biochemistry/pharmacy degree

Job description

Principal Technologist or Associate Scientist, Assay Development

Does it excite you to work with ligand binding and cell based assay development, and do you have experience with assay design and qualification? If this sounds like you, and you are ready to take on a broad range of responsibilities, then you could be our new colleague.

Your new position

We are seeking a Laboratory-based Principal Technologist, or a scientist with an interest in lab work, to join the Department of Pharmacokinetics, Immunogenicity & Bioanalytical Sciences. In this role, you will play a key part in developing and qualifying high-quality assays to detect our novel peptide therapeutics and characterize immunogenicity during preclinical and clinical development. You will support the development of various assays, contribute to technology transfer to contract research organizations (CROs), and generate critical reagents essential to our assay pipeline.

We offer exciting responsibilities:

• Development and qualification of cell-based and ligand binding immunogenicity assays (anti-drug antibodies and neutralizing antibodies)
• Support general ligand binding assay development, qualification, and sample analysis as required
• Production, purification, and characterization of critical reagents
• Cell culture maintenance and optimization for assay purposes
• Support assay transfer and validation to contract research organizations (CROs)
• Data analysis, interpretation, and comprehensive documentation

Your profile

We are looking for a dedicated and detail-oriented Laboratory-based Principal Technologist or a Scientist, with a genuine interest in lab work, a passion for assay development and analytical method science. You bring hands‑on expertise in bioanalytical techniques and a strong understanding of how biomolecules behave in various analytical systems. You are a recognized technical contributor, highly motivated, and possesses strong communication skills in English. You thrive in a collaborative environment and take pride in creating comprehensive documentation of your work.

• Laboratory technologist qualification (e.g., biomedical laboratory technology) or a scientific degree (e.g., biology, biochemistry, pharmacy) with a clear interest in hands‑on laboratory work
• 5 to 10 years of hands‑on experience in development and qualification of assays including immunogenicity assays, biomarker assays, and quantitative ligand binding assays (cell‑based and ligand binding formats)
• Good understanding of various analytical techniques used for biomolecules (e.g., ELISA, electrochemiluminescence, affinity chromatography, surface plasmon resonance, or related methods)
• Thorough understanding of analytical methods for quantifying, detecting, and characterizing drug‑induced immunogenicity
• Excellent documentation and data analysis skills
• Proven ability to master core processes independently while being an effective team collaborator
• Proficient in English, both written and oral communication

Your new team

The Department of Pharmacokinetics, Immunogenicity & Bioanalytical Sciences—a dedicated group of specialists collaborating to understand the behavior of our drug candidates on efficacy and safety. You will work alongside experienced scientists and technologists committed to advancing high‑quality bioanalytical support for our pipeline.

Let's bond and be bold

We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. #LI-Onsite Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.